Four years ago, we launched our best-selling Straumann BLT implant in response to patient requirements for shorter implant treatment times. BLT has been a key growth driver and still has significant potential but, being apically-tapered, it does not address the entire range of indications in the immediacy segment, which accounts for one in every four implants placed. In 2015, we therefore began working with the world’s top experts to develop an entirely new fully-tapered implant that would deliver a new level of confidence not just in immediacy but also in a broad range of other indications.

The result is Straumann BLX, which is designed for optimum primary stability in all bone classes and predictable outcomes, even in complex cases. To make life simpler, its entire prosthetic range uses the same connection, while its unique advanced design, combined with our Roxolid and SLActive technology, creates a new generation implant system which is integrated in a complete range of digital and prosthetic solutions for all indications.

The full launch is expected in 2019.